JP2022513490A5 - - Google Patents

Info

Publication number
JP2022513490A5
JP2022513490A5 JP2021534228A JP2021534228A JP2022513490A5 JP 2022513490 A5 JP2022513490 A5 JP 2022513490A5 JP 2021534228 A JP2021534228 A JP 2021534228A JP 2021534228 A JP2021534228 A JP 2021534228A JP 2022513490 A5 JP2022513490 A5 JP 2022513490A5
Authority
JP
Japan
Prior art keywords
disease
syndrome
autoimmune
fibrosis
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066575 external-priority patent/WO2020131717A1/en
Publication of JP2022513490A publication Critical patent/JP2022513490A/ja
Publication of JP2022513490A5 publication Critical patent/JP2022513490A5/ja
Priority to JP2024001373A priority Critical patent/JP2024041867A/ja
Pending legal-status Critical Current

Links

JP2021534228A 2018-12-16 2019-12-16 遺伝子編集線維芽細胞の治療的使用 Pending JP2022513490A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001373A JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780289P 2018-12-16 2018-12-16
US62/780,289 2018-12-16
PCT/US2019/066575 WO2020131717A1 (en) 2018-12-16 2019-12-16 Therapeutic uses of gene edited fibroblasts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001373A Division JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Publications (2)

Publication Number Publication Date
JP2022513490A JP2022513490A (ja) 2022-02-08
JP2022513490A5 true JP2022513490A5 (enExample) 2023-06-28

Family

ID=71102289

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021534228A Pending JP2022513490A (ja) 2018-12-16 2019-12-16 遺伝子編集線維芽細胞の治療的使用
JP2024001373A Pending JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001373A Pending JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Country Status (6)

Country Link
US (1) US20220025332A1 (enExample)
EP (1) EP3894546A4 (enExample)
JP (2) JP2022513490A (enExample)
AU (1) AU2019403057B2 (enExample)
CA (1) CA3123408A1 (enExample)
WO (1) WO2020131717A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109837250B (zh) * 2019-01-15 2021-10-12 中国农业科学院兰州兽医研究所 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6849612B2 (en) * 1993-01-21 2005-02-01 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
DE69233010T2 (de) * 1991-07-15 2004-02-19 Oklahoma Medical Research Foundation, Oklahoma Universale spenderzellen
US5602307A (en) * 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
JPH06319585A (ja) * 1992-11-26 1994-11-22 Fujisawa Pharmaceut Co Ltd 抗体およびその製造法
JPH09512021A (ja) * 1994-04-19 1997-12-02 ザ ユニバーシティ オブ カンサス Ｉｃａｍ−１／ｌｆａ−１ 短鎖ペプチドおよび該ペプチドの使用方法
US6939712B1 (en) * 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
JP2002542200A (ja) * 1999-04-21 2002-12-10 久光製薬株式会社 免疫寛容を誘発するｄ型ポリペプチドおよびその使用方法
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
JP2008542252A (ja) * 2005-05-26 2008-11-27 インターサイテックス リミティド 同種真皮繊維芽細胞を用いる組織修復
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
AR080219A1 (es) * 2010-02-18 2012-03-21 Osiris Therapeutics Inc Productos de membranas corionicas inmunocompatibles
AU2014248605B2 (en) * 2013-03-12 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for modification of HLA
EP3229586B1 (en) * 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
AU2016206870B2 (en) * 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
CN104611370A (zh) * 2015-01-16 2015-05-13 深圳市科晖瑞生物医药有限公司 一种剔除β2-微球蛋白基因片段的方法
CA2988854A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
KR102796744B1 (ko) * 2015-06-09 2025-04-15 에디타스 메디신, 인코포레이티드 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물

Similar Documents

Publication Publication Date Title
Cohen Mesenchymal stem cell transplantation in multiple sclerosis
US20200283727A1 (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
JP2023159370A (ja) 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用
Bittencourt et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers
US8241621B2 (en) Stem cell mediated treg activation/expansion for therapeutic immune modulation
ES2751692T3 (es) Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos
US20220088190A1 (en) Compositions and Methods for Targeting Mutant RAS
Zhou et al. Boosting interleukin-10 production: therapeutic effects and mechanisms
US20170246217A1 (en) Use of cord blood plasma to treat nk cell-mediated diseases and ifn-γ mediated diseases
US20170166869A1 (en) Biologically optimized adult mesenchymal stem cells
JP7808849B2 (ja) ハイポテンシャル多能性幹細胞
CN110691600A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
Crooks et al. Immune reconstitution: from stem cells to lymphocytes
Parkman Is chronic graft versus host disease an autoimmune disease?
JP2023522213A5 (enExample)
Vandenbark et al. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress
JP2024520952A (ja) 免疫原性ペプチドを使用した改善された処置方法
US20250034230A1 (en) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
CN108815188A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
JP2023525079A (ja) フマレート関連疾患の併用療法
Tyndall Cellular therapy of systemic lupus erythematosus
Ash et al. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD
AU2019403057B2 (en) Therapeutic uses of gene edited fibroblasts
JP2023536386A (ja) Ｉｃａｍ調節剤を用いた治療の方法
JP2003521439A (ja) 末梢単球の増殖を促進するためのｃｄ１３７の使用